Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.1K
Disorders of Hemostasis01:24

Disorders of Hemostasis

831
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
831
Probability Laws01:49

Probability Laws

40.8K
Overview
40.8K
Multiple Allele Traits01:49

Multiple Allele Traits

34.2K
The Concept of Multiple Allelism
34.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trp83 is vital to the interaction with phospholipids in γ-carboxyglutamic acid domain of protein C.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Simulated Aging Studies on Porcelain Restoration Adhesives for Conservation in Chinese Museums.

Materials (Basel, Switzerland)·2026
Same author

Thrombosis Caused by Factor XI Gly397Ser Mutation with Enhanced Procoagulant Activity.

Thrombosis and haemostasis·2025
Same author

Fibrinogen dysfunction and fibrinolysis state in patients with hepatitis B-related cirrhosis.

Hematology (Amsterdam, Netherlands)·2024
Same author

Electrical impedance tomography as a bedside assessment tool for COPD treatment during hospitalization.

Frontiers in physiology·2024
Same author

Automated and ultrasensitive point-of-care glycoprotein detection using boronate-affinity enhanced organic electrochemical transistor patch.

Biosensors & bioelectronics·2024

Related Experiment Video

Updated: Jun 23, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

335

Heterozygous Prothrombin Mutation-Associated Thrombophilia.

Xi Wu1, Lei Li1, Zhengjing Lu1

  • 1Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Thrombosis and Haemostasis
|June 24, 2024
PubMed
Summary

Heterozygous prothrombin mutations are linked to an increased risk of venous thromboembolism (VTE). These genetic variants enhance blood clot formation by affecting antithrombin resistance and protein C activation.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.0K

Related Experiment Videos

Last Updated: Jun 23, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

335
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.0K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.0K

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Hereditary thrombophilia predisposes individuals to venous thromboembolism (VTE) through thrombotic mutations.
  • While homozygous prothrombin mutations cause bleeding, heterozygous forms are rarely linked to thrombosis.
  • This study investigates the thrombotic risk associated with heterozygous prothrombin mutations.

Purpose of the Study:

  • To identify and characterize heterozygous prothrombin mutations in patients with unprovoked VTE or a family history of thrombosis.
  • To elucidate the thrombotic mechanisms underlying these mutations through family investigations and functional assays.
  • To assess the hypercoagulability and thrombin generation potential in mutation carriers.

Main Methods:

  • Genetic screening of 347 patients for thrombosis and hemostasis variants.
  • Family investigations and thrombin generation tests (TGT) for heterozygous prothrombin mutation carriers.
  • Functional assays of novel mutants to determine their impact on thrombin activity and protein C activation.

Main Results:

  • Heterozygous prothrombin mutations were found in 3.5% of patients, including three novel mutations (Phe382Ser, Phe382Leu, Asp597Tyr) and previously reported ones (Arg541Trp, Arg596Gln).
  • Of 42 identified mutation carriers, 64.3% experienced thrombotic events.
  • TGT revealed hypercoagulability in carriers, with Arg596Gln and Arg541Trp showing the highest thrombin generation. Phe382 mutations impaired protein C activation, while Asp597Tyr showed mild reductions in antithrombin inactivation and protein C activation.

Conclusions:

  • Heterozygous prothrombin mutations are a potential genetic risk factor for VTE.
  • These mutations increase coagulation activity by resisting antithrombin or impairing protein C pathway activity.
  • Understanding these mechanisms is crucial for assessing thrombosis risk in affected individuals.